| microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer FM Buffa, C Camps, L Winchester, CE Snell, HE Gee, H Sheldon, ... Cancer research 71 (17), 5635-5645, 2011 | 367 | 2011 |
| Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells E Favaro, K Bensaad, MG Chong, DA Tennant, DJP Ferguson, C Snell, ... Cell metabolism 16 (6), 751-764, 2012 | 364 | 2012 |
| Vessel co‐option in primary human tumors and metastases: an obstacle to effective anti‐angiogenic treatment? T Donnem, J Hu, M Ferguson, O Adighibe, C Snell, AL Harris, KC Gatter, ... Cancer medicine 2 (4), 427-436, 2013 | 276 | 2013 |
| Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy A McIntyre, S Patiar, S Wigfield, J Li, I Ledaki, H Turley, R Leek, C Snell, ... Clinical cancer research 18 (11), 3100-3111, 2012 | 261 | 2012 |
| A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis M Masiero, FC Simões, HD Han, C Snell, T Peterkin, E Bridges, ... Cancer cell 24 (2), 229-241, 2013 | 252 | 2013 |
| DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In VivoRole of DLL4 in Tumor Resistance to Anti-VEGF Therapy JL Li, RCA Sainson, CE Oon, H Turley, R Leek, H Sheldon, E Bridges, ... Cancer research 71 (18), 6073-6083, 2011 | 248 | 2011 |
| BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1tumour phenotype C Snell, M Krypuy, EM Wong, MB Loughrey, A Dobrovic Breast Cancer Research 10 (1), 1-8, 2008 | 145 | 2008 |
| Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer SR Lord, WC Cheng, D Liu, E Gaude, S Haider, T Metcalf, N Patel, ... Cell metabolism 28 (5), 679-688. e4, 2018 | 97 | 2018 |
| Suppressor of cytokine signaling 3 limits protection of leukemia inhibitory factor receptor signaling against central demyelination B Emery, HS Cate, M Marriott, T Merson, MD Binder, C Snell, PY Soo, ... Proceedings of the National Academy of Sciences 103 (20), 7859-7864, 2006 | 86 | 2006 |
| Disrupting Hypoxia-Induced Bicarbonate Transport Acidifies Tumor Cells and Suppresses Tumor GrowthHypoxic NDBT Induction Promotes Tumor Growth A McIntyre, A Hulikova, I Ledaki, C Snell, D Singleton, G Steers, P Seden, ... Cancer research 76 (13), 3744-3755, 2016 | 84 | 2016 |
| PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer SJ Fan, C Snell, H Turley, JL Li, R McCormick, SMW Perera, S Heublein, ... Oncogene 35 (23), 3004-3015, 2016 | 71 | 2016 |
| Expression of CDCA3 is a prognostic biomarker and potential therapeutic target in non–small cell lung cancer MN Adams, JT Burgess, Y He, K Gately, C Snell, SD Zhang, JD Hooper, ... Journal of Thoracic Oncology 12 (7), 1071-1084, 2017 | 61 | 2017 |
| Proline-hydroxylated hypoxia-inducible factor 1α (HIF-1α) upregulation in human tumours CE Snell, H Turley, A McIntyre, D Li, M Masiero, CJ Schofield, KC Gatter, ... PLoS One 9 (2), e88955, 2014 | 55 | 2014 |
| Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients KK Wong, DM Gascoyne, PJ Brown, EJ Soilleux, C Snell, H Chen, L Lyne, ... Leukemia 28 (2), 362-372, 2014 | 54 | 2014 |
| EBV microRNA-BHRF1-2-5p targets the 3′ UTR of immune checkpoint ligands PD-L1 and PD-L2 AS Cristino, J Nourse, RA West, MB Sabdia, SC Law, J Gunawardana, ... Blood 134 (25), 2261-2270, 2019 | 46 | 2019 |
| CSF1R-dependent macrophages control postnatal somatic growth and organ maturation S Keshvari, M Caruso, N Teakle, L Batoon, A Sehgal, OL Patkar, ... PLoS Genetics 17 (6), e1009605, 2021 | 35 | 2021 |
| SOCS3 negatively regulates LIF signaling in neural precursor cells B Emery, TD Merson, C Snell, KM Young, M Ernst, TJ Kilpatrick Molecular and Cellular Neuroscience 31 (4), 739-747, 2006 | 35 | 2006 |
| Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma T Kryza, T Khan, S Puttick, C Li, KA Sokolowski, WC Brian, T Cuda, ... Theranostics 10 (9), 4116, 2020 | 26 | 2020 |
| The molecular function of kallikrein‐related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer T Kryza, N Bock, S Lovell, A Rockstroh, ML Lehman, A Lesner, ... Molecular Oncology 14 (1), 105-128, 2020 | 18 | 2020 |
| Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine ZY Oo, M Proctor, AJ Stevenson, D Nazareth, M Fernando, SM Daignault, ... Molecular oncology 13 (7), 1503-1518, 2019 | 17 | 2019 |
